Currently out of the existing stock ratings of David Roman, 39 are a BUY (39.39%), 48 are a HOLD (48.48%), 12 are a SELL (12.12%).

David Roman

Work Performance Price Targets & Ratings Chart

Analyst David Roman, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 60.17% that have a potential upside of 15.7% achieved within 177 days.

David Roman’s has documented 192 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BAX, Baxter International at 15-Jul-2026.

Wall Street Analyst David Roman

Analyst best performing recommendations are on HQY (HEALTHEQUITY).
The best stock recommendation documented was for HQY (HEALTHEQUITY) at 1/9/2026. The price target of $89 was fulfilled within 3 days with a profit of $5.15 (5.47%) receiving and performance score of 18.23.

Average potential price target upside

of $30.42 (15.11%) on ISRG (INTUITIVE SURGICAL).
of $23.08 (15.55%) on SYK (STRYKER).
of $18.31 (26.62%) on EW (EDWARDS LIFESCIENCES CORP).

BAX Baxter International ISRG Intuitive Surgical NUVA NuVasive MDT Medtronic PLC HAE Haemonetics VAR Varian Medical Systems SYK Stryker DOCS Doximity EW Edwards Lifesciences Corp IRTC iRhythm Technologies SOLV Solventum Corp. ABT Abbott Laboratories GMED Globus Medical COO The Cooper Companies Common Stock HQY HealthEquity LIVN LivaNova PLC TDOC Teladoc TNDM Tandem Diabetes Care ZBH Zimmer Biomet Holdings BSX Boston Scientific Corp PODD Insulet GEHC GE HealthCare Technologies BDX Becton Dickinson and Company

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Joanne Wuensch (CITI)